Viridian Therapeutics, Inc.
VRDN
$20.99
-$0.82-3.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.17% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.17% | 0.00% | |||
| Cost of Revenue | 1,407.06% | -97.59% | |||
| Gross Profit | -1,424.86% | 97.62% | |||
| SG&A Expenses | 18.20% | 9.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.74% | 7.30% | |||
| Operating Income | -13.74% | -7.31% | |||
| Income Before Tax | -15.90% | -9.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.90% | -9.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.90% | -9.01% | |||
| EBIT | -13.74% | -7.31% | |||
| EBITDA | -13.77% | -7.33% | |||
| EPS Basic | -15.62% | -279.31% | |||
| Normalized Basic EPS | -15.54% | -6.95% | |||
| EPS Diluted | -15.62% | -279.31% | |||
| Normalized Diluted EPS | -15.54% | -6.95% | |||
| Average Basic Shares Outstanding | 0.31% | 1.61% | |||
| Average Diluted Shares Outstanding | 0.31% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||